[1]张娇,黄纯海,毛辉.KDELR2在胶质瘤中的表达及临床意义：基于组织芯片技术分析[J].中国临床神经外科杂志,2024,29(03):151-156176.[doi:10.13798/j.issn.1009-153X.2024.03.006]
　ZHANG Jiao,HUANG Chun-hai,MAO Hui.Expression of KDELR2 in glioma tissues and its clinical significance: an analysis based on tissue microarray technology[J].,2024,29(03):151-156176.[doi:10.13798/j.issn.1009-153X.2024.03.006]
点击复制

KDELR2在胶质瘤中的表达及临床意义：基于组织芯片技术分析()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
29
期数:
2024年03期
页码:
151-156176
栏目:
论著
出版日期:
2024-03-31

文章信息/Info

Title:
Expression of KDELR2 in glioma tissues and its clinical significance: an analysis based on tissue microarray technology
文章编号:
1009-153X（2024）03-0151-06
作者:
张娇; 黄纯海; 毛辉
416000湖南吉首，湘西自治州人民医院（吉首大学第一附属医院）神经外科（张娇、黄纯海、毛辉）
Author(s):
ZHANG Jiao;  HUANG Chun-hai;  MAO Hui
Department of Neurosurgery, Xiangxi Autonomous Prefecture People's Hospital (The First Affiliated Hospital of Jishou University), Jishou 416000, China
关键词:
脑胶质瘤; KDELR2; 组织芯片; 预后; 基因表达
Keywords:
Glioma;  KDELR2;  Tissue microarray technology;  Prognosis;  Gene expression
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2024.03.006
文献标志码:
A
摘要:
目的 探讨KDELR2在脑胶质瘤中的表达及其与胶质瘤病人临床特征、病理特征和预后的关系。方法 选择组织芯片HBraG180Su01作为实验标本，收集并整理完整的临床资料。免疫组化染色检查胶质瘤组织KDELR2的表达，分析KDELR2的表达水平与胶质瘤病人临床特征、病理特征以及预后的关系。结果 最终纳入165例胶质瘤。免疫组化染色显示，KDELR2主要表达于胶质瘤细胞的细胞质。胶质瘤KDELR2表达阳性率高达98.18 %；KDELR2表达水平与胶质瘤WHO分级、复发状态、PDL1表达及病人年龄、生存状态呈显著相关（P<0.05），与胶质瘤Ki-67、EGFR表达及病人性别无明显关系（P>0.05）。Cox比例回归风险模型分析显示，KDELR2高表达是胶质瘤病人生存预后不良的独立危险因素（P<0.05）；生存曲线分析显示，KDELR2高表达组总体生存期和无进展生存期较KDELR2低表达组明显缩短（P<0.05）。结论 胶质瘤KDELR2呈高表达，与胶质瘤WHO分级、复发显著相关，并与胶质瘤病人的生存预后显著相关。这提示KDELR2可作为胶质瘤靶向治疗的一个潜在靶点。
Abstract:
Objective To investigate the expression of KDELR2 in glioma tissues and its relationship with clinical and pathological features, and prognosis of glioma patients. Methods The HBraG180Su01 tissue microarray was selected as the experimental specimen, and their clinical data were collected. Immunohistochemical staining was used to detect the expression of KDELR2 in glioma tissues, and the relationships between KDELR2 expression level and clinical and pathological features, and prognosis of glimoa patients were analyzed. Results A total of 165 glioma cases were finally included. Immunohistochemical staining showed that KDELR2 was mainly located in the cytoplasm of glioma cells. The positive rate of KDELR2 expression in glioma tissues was as high as 98.18%. KDELR2 expression level was significantly correlated with WHO grade, recurrence status, and PDL1 expression, patients' age, and survival status (P<0.05), but not significantly correlated with patients' gender, and expression levels of Ki-67 and EGFR (P>0.05). Cox proportional hazards regression risk model analysis showed that high expression of KDELR2 was an independent risk factor for poor survival of glioma patients (P<0.05). Kaplan-Meier survival curve analysis showed that the overall survival and progression-free survival of patients with high expression of KDELR2 were significantly shorter than those with low expression of KDELR2 (P<0.05). Conclusions KDELR2 is highly expressed in gliomas, is significantly correlated with WHO grade, tumor recurrence, and patients' prognosis. Our results suggest that KDELR2 may be a potential target for therapy of gliomas.

参考文献/References:

[1]OSTROM QT, PRICE M, NEFF C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019 [J]. Neuro Oncol, 2022, 24(Suppl 5): v1-v95.
[2]JIANG T, NAM D H, RAM Z, et al. Clinical practice guidelines for the management of adult diffuse gliomas [J]. Cancer Lett, 2021, 499: 60-72.
[3]DELVE D, HEILAND DH, FRANCO P, et al. Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system [J]. J Neurooncol, 2019, 141(1): 223-233.
[4]RAYKHEL I, ALANEN H, SALO K, et al. A molecular specificity code for the three mammalian KDEL receptors [J]. J Cell Biol, 2007, 179(6): 1193-204.
[5]BAJAJ R, KUNDU ST, GRZESJIWUAK CL, et al. IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgimediated secretion [J]. Oncogene, 2020, 39(37): 5979-5994.
[6]LIAO Z, SHE C, MA L, et al. KDELR2 promotes glioblastoma tumorigenesis targeted by HIF1a via mTOR signaling pathway [J]. Cell Mol Neurobiol, 2019, 39(8): 1207-1215.
[7]ZHANG G, WANG B, CHENG S, et al. KDELR2 knockdown synergizes with temozolomide to induce glioma cell apoptosis through the CHOP and JNK/p38 pathways [J]. Transl Cancer Res, 2021, 10(7): 3491-3506.
[8]MAO H, NIAN J, WANG Z, et al. KDELR2 is an unfavorable prognostic biomarker and regulates CCND1 to promote tumor progression in glioma [J]. Pathol Res Pract, 2020, 216(7): 152996.
[9]SAKER Z, BAHMAD HF, FARES Y, et al. Prognostic impact of adenylyl cyclase-associated protein 2 (CAP2) in glioma: a clinicopathological study [J]. Heliyon, 2020, 6(1): e03236.
[10]BRAUER P, PARKER JL, GERONDOPOULOS A, et al. Structural basis for pH-dependent retrieval of ER proteins from the Golgi by the KDEL receptor [J]. Science, 2019, 363(6431): 1103-1107.
[11]CAPITANI M, SALLESE M. The KDEL receptor: new functions for an old protein [J]. FEBS Lett, 2009, 583(23): 3863-3871.
[12]TRYCHTA KA, BACK S, HENDERSON MJ, et al. KDEL receptors are differentially regulated to maintain the ER proteome under calcium deficiency [J]. Cell Rep, 2018, 25(7): 1829-1840 e6.
[13]SHAHEIN SA, ABOUL-ENEIN AM, HIGAZY IM, et al. Targeted anticancer potential against glioma cells of thymoquinone delivered by mesoporous silica core-shell nanoformulations with pHdependent release [J]. Int J Nanomedicine, 2019, 14: 5503-5526.

相似文献/References:

[1]付　锴　江普查　宫　睿　王　伟.表达VASH1基因的人脑胶质瘤U-87MG细胞对化疗药物敏感性的变化[J].中国临床神经外科杂志,2016,(01):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
　FU Kai,JIANG Pu-cha,GONG Rui,et al.Effect of lentiviral vector-mediated VASH1 gene on chemosensitivity of human glioma U-87MG cells[J].,2016,(03):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
[2]崔焕喜,柳　琛.多模态MRI、神经导航和超声在脑胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(11):721.[doi:10.13798/j.issn.1009-153X.2016.11.027]
[3]闫　珊　徐善才.多学科护理照顾模式对脑胶质瘤术后病人自我护理能力的影响[J].中国临床神经外科杂志,2017,(05):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
　YAN Shan,XU Shan-cai..Effects of multi-subjects nursing care model on self-care ability in patients with brain glioma after operation[J].,2017,(03):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
[4]罗似亮　夏之柏.脑胶质瘤病人脑脊液Midkine表达的临床意义[J].中国临床神经外科杂志,2017,(06):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
　LUO Si-liang,XIA Zhi-bo..Clinical meanings of midkine expression in cerebrospinal fluid of patients with gliomas[J].,2017,(03):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
[5]呼铁民　褚会松　田　甜　王昆鹏　杨国军　杨立军　王维兴.脑胶质瘤ADAM17与EGFR的表达及临床意义[J].中国临床神经外科杂志,2017,(08):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
　HU Tie-min,CHU Hui-song,TIAN Tian,et al.Expressions of ADAM17 and EGFR in gliomas tissues and their clinical meanings[J].,2017,(03):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
[6]汪超甲 综述　王　辉 审校.脑胶质瘤化疗现状及耐药机制的研究进展[J].中国临床神经外科杂志,2017,(11):791.[doi:10.13798/j.issn.1009-153X.2017.11.023]
[7]高剑峰　姚庆和　李晓辉　龙宇波　陈振波.脑胶质瘤miR-9、PPARγ表达水平及临床意义[J].中国临床神经外科杂志,2018,(01):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
　GAO Jian-feng,YAO Qing-he,LI Xiao-hui,et al.Expressions of miR-9 and PPARγ in human brain gliomas and their clinical meanings[J].,2018,(03):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
[8]刘　靖　吴立权　黄书岚.聚焦解决模式对脑胶质瘤术后病人自我管理效能感及生命意义的影响[J].中国临床神经外科杂志,2018,(03):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
　LIU Jing,WU Li-quan,HUANG Shu-lan..Effects of solution focused intervention on self-management efficacy and meanings of life in the patients with gliomas after surgery[J].,2018,(03):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
[9]刘　炎　杭春华.脑胶质瘤卒中误诊为脑动静脉畸形并出血1例[J].中国临床神经外科杂志,2018,(06):448.[doi:10.13798/j.issn.1009-153X.2018.06.025]
[10]刘东明　胡新华　刘　永　陈　玖　刘宏毅.脑胶质瘤病人静息态默认模式网络研究进展[J].中国临床神经外科杂志,2018,(12):821.[doi:10.13798/j.issn.1009-153X.2018.12.022]

备注/Memo

备注/Memo:
（2023-01-06收稿，2023-11-02修回）
基金项目：湖南省卫健委课题（202104091193）；吉首大学第一附属医院指导性项目（Jdlc2002）
通信作者：毛　辉，Email：niningerlai@163.com
更新日期/Last Update: 2024-03-31